Elranatamab(Elranatamab) - 药物靶点：BCMA x CD3_在研适应症：多发性骨髓瘤，复发性多发性骨髓瘤，阴燃多发性骨髓瘤_专利_临床

概要

基本信息

药物类型

双特异性T细胞结合器

别名

Elranatamab (USAN)、elranatamab-bcmm、PF-06863135

+ [4]

靶点

BCMA x CD3

作用机制

BCMA调节剂(B细胞成熟蛋白调节剂)、CD3刺激剂(T细胞表面糖蛋白CD3复合体刺激剂)

治疗领域

癌症免疫系统疾病心血管疾病+ [2]

在研适应症

多发性骨髓瘤复发性多发性骨髓瘤阴燃多发性骨髓瘤

非在研适应症-

原研机构

Pfizer Inc.

在研机构

Pfizer Japan, Inc.Pfizer Europe MA EEIG

Pfizer Inc.

+ [1]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2023-08-14),

多发性骨髓瘤

最高研发阶段(中国)申请上市

特殊审评优先审评 (美国)、突破性疗法 (美国)、快速通道 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、优先药物（PRIME） (欧盟)、优先审评 (中国)、附条件批准 (欧盟)、快速通道 (欧盟)

登录后查看首次获批时间轴

序列信息

Sequence Code 10256963L

来源: *****

Sequence Code 315617079L

来源: *****

Sequence Code 432311657H

来源: *****

Sequence Code 432311660H

来源: *****

关联

36

项与 Elranatamab 相关的临床试验

NCT06581848 / Not yet recruitingN/A

Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).

This study is to assess the safety and effectiveness of Elranatamab in the real-world clinical settings for the treatment of patients with multiple myeloma in Korea.

开始日期2024-10-31

申办/合作机构

Pfizer Inc.

NCT06483100 / Not yet recruiting临床2期IIT

Measurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance Using Peripheral Blood Clonotypic Mass Spectrometry

This study evaluates an individualized approach combining highly active maintenance treatment with elranatamab with peripheral blood-based clonotypic measurable residual disease (MRD) testing in patients with newly diagnosed multiple myeloma. The overall goal is to generate efficacy and tolerability data for a personalized maintenance approach using peripheral blood-based clonotypic mass spectrometry MRD testing (the EasyM assay) to guide post-autologous hematopoietic cell transplant (AHCT) maintenance with elranatamab for this patient population.

开始日期2024-09-30

申办/合作机构

Washington University School of Medicine

[+3]

NCT06569147 / Not yet recruiting临床1/2期IIT

A Phase I/II, Open Label, Study to Evaluate Safety, Tolerability and Efficacy of Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis

This study will evaluate the safety, tolerability and efficacy of elranatamab in patients with relapsed or refractory AL amyloidosis.

开始日期2024-09-01

申办/合作机构

The Brigham & Women's Hospital, Inc.

100 项与 Elranatamab 相关的临床结果

登录后查看更多信息

100 项与 Elranatamab 相关的转化医学

登录后查看更多信息

100 项与 Elranatamab 相关的专利（医药）

登录后查看更多信息

16

项与 Elranatamab 相关的文献（医药）

2024-12-31·mAbs

Antibodies to watch in 2024

Article

作者: Reichert, Janice M ; Kaplon, Hélène ; Crescioli, Silvia ; Wang, Lin ; Visweswaraiah, Jyothsna ; Chenoweth, Alicia

The 'Antibodies to Watch' article series provides an annual summary of commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical development, regulatory review, and those recently granted a first approval in any country. In this installment, we discuss key details for 16 antibody therapeutics granted a first approval in 2023, as of November 17 (lecanemab (Leqembi), rozanolixizumab (RYSTIGGO), pozelimab (VEOPOZ), mirikizumab (Omvoh), talquetamab (Talvey), elranatamab (Elrexfio), epcoritamab (EPKINLY), glofitamab (COLUMVI), retifanlimab (Zynyz), concizumab (Alhemo), lebrikizumab (EBGLYSS), tafolecimab (SINTBILO), narlumosbart (Jinlitai), zuberitamab (Enrexib), adebrelimab (Arelili), and divozilimab (Ivlizi)). We briefly review 26 product candidates for which marketing applications are under consideration in at least one country or region, and 23 investigational antibody therapeutics that are forecast to enter regulatory review by the end of 2024 based on company disclosures. These nearly 50 product candidates include numerous innovative bispecific antibodies, such as odronextamab, ivonescimab, linvoseltamab, zenocutuzumab, and erfonrilimab, and antibody-drug conjugates, such as trastuzumab botidotin, patritumab deruxtecan, datopotamab deruxtecan, and MRG002, as well as a mixture of two immunocytokines (bifikafusp alfa and onfekafusp alfa). We also discuss clinical phase transition and overall approval success rates for antibody therapeutics, which are crucial to the biopharmaceutical industry because these rates inform decisions about resource allocation. Our analyses indicate that these molecules have approval success rates in the range of 14-32%, with higher rates associated with antibodies developed for non-cancer indications. Overall, our data suggest that antibody therapeutic development efforts by the biopharmaceutical industry are robust and increasingly successful.

2024-02-01·Current medical research and opinion

A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician’s choice of treatment in patients with triple-class exposed/refractory multiple myeloma

Article

作者: Nador, Guido ; Hlavacek, Patrick ; Hu, Yannan ; Aydin, Didem ; LeBlanc, Thomas W ; Schepart, Alex ; Mol, Isha ; Chu, Haitao ; Cappelleri, Joseph C

INTRODUCTION:

For patients with triple-class exposed/refractory multiple myeloma (TCE/R MM), prognosis is poor and effective treatment options are limited. Elranatamab is a novel B-cell maturation antigen (BCMA)- and CD3-directed bispecific antibody which was approved by the US Food and Drug Administration in August 2023 and demonstrated safety and efficacy in patients with TCE/R MM in the phase 2, single-arm MagnetisMM-3 trial (NCT04649359). To compare the effectiveness of elranatamab vs physician's choice of treatment (PCT) in the absence of head-to-head comparative data, a matching-adjusted indirect comparison (MAIC) was conducted.

METHODS:

Individual patient data from MagnetisMM-3 (Cohort A [BCMA-naïve] N = 123, 14.7 months of follow-up) were reweighted to match published summary data from two real-world studies of PCT in patients with TCE/R MM (LocoMMotion and MAMMOTH) using a propensity score-type logistic regression. Unanchored MAIC analyses were conducted according to National Institute for Health and Care Excellence (NICE) Decision Support Unit (DSU) 18 guidance.

RESULTS:

Compared with PCT in LocoMMotion, elranatamab was associated with a significantly higher objective response rate (ORR rate difference: 37.52; 95% CI 26.20-48.83; odds ratio: 4.85; 95% CI 2.85-8.23) and complete or stringent complete response rate (≥CR rate difference: 42.29; 95% CI 31.84-52.74; odds ratio: 184.01; 95% CI 24.66-1372.86), longer progression-free survival (PFS HR 0.32; 95% CI 0.20-0.49), and overall survival (OS HR 0.62; 95% CI 0.40-0.94). Compared with PCT in MAMMOTH, elranatamab was associated with significantly higher ORR (rate difference: 28.14; 95% CI 16.77-39.52; odds ratio: 3.24; 95% CI 1.98-5.32) and ≥ CR (rate difference: 26.22; 95% CI 16.40-36.05; odds ratio: 5.48; 95% CI 2.88-10.44), as well as longer PFS (HR 0.25; 95% CI 0.17-0.37) and OS (HR 0.49; 95% CI 0.33-0.71). Sensitivity analysis results were consistent with the base case.

CONCLUSION:

In the MAIC, elranatamab was consistently associated with improved rates and depth of response and significantly longer PFS and OS versus PCT in LocoMMotion and MAMMOTH.

2023-12-02·Expert opinion on biological therapy

Bispecific antibodies as monotherapy or in combinations for hematological malignancies: latest updates from the EHA 2023 annual meeting

Article

作者: Zhang, Peng ; Jiang, Zhongxing ; Han, Lijie ; Sun, Hao ; Yu, Jifeng ; Li, Xingchen

According to recent research, bispecific antibodies (BsAbs) are a promising new immunotherapy method. Various BsAb forms are constantly being developed. In the year 2022 alone, four BsAbs (tebentafusp, faricimab, mosunetuzumab, and teclistamab) were approved for clinical applications. BsAbs including odronextamab, talquetamab, linvoseltamab, and elranatamab are being actively evaluated in different clinical studies. Preliminary results show promising response rates in relapsed/refractory follicular lymphoma (RRFL), relapsed/refractory diffuse large B-cell lymphoma (RRDLBCL), and relapsed/refractory multiple myeloma (RRMM), especially in heavily pretreated patients, including those who have progressed after proteasome inhibitors, immunomodulatory drugs, anti-CD38 antibodies, and CAR-T therapies. We summarized data published at the 28th European Hematology Association (EHA) annual meeting, which was held in Frankfurt between 8 June 2023 and 11 June 2023 on BsAbs monotherapy or combination therapy for RRFL, RRDLBCL, and RRMM.

205

项与 Elranatamab 相关的新闻（医药）

2024-09-12

·PMLiVE

Pfizer’s Elrexfio accepted by SMC to treat relapsed and refractory multiple myeloma

Pfizer’s Elrexfio (elranatamab) has been accepted by the Scottish Medicines Consortium (SMC) for use as a monotherapy in adults with relapsed and refractory multiple myeloma. The BCMA-directed bispecific antibody will now be available on the NHS in Scotland on an interim basis to treat patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and demonstrated disease progression on the last therapy. Affecting around 475 people in Scotland every year, multiple myeloma is an incurable cancer that forms in a type of white blood cell called a plasma cell. The disease often affects several areas of the body and follows a relapsing-remitting pattern, meaning it usually returns after a period of remission and further treatment is required. Administered as a subcutaneous injection, Elrexfio is designed to help the immune system recognise and kill cancer cells by binding to both BCMA, which is highly expressed in multiple myeloma, and CD3 receptors found on the surface of T cells. The SMC’s decision, which is subject to ongoing evaluation and future reassessment, was supported by positive results from the mid-stage MagnetisMM-3 study. Pfizer recently shared detailed overall survival (OS) results from the trial, demonstrating a median OS of 24.6 months in cohort A, which enrolled patients without prior BCMA-directed therapy. After more than two years of follow-up, the overall response rate for patients on Elrexfio was 61%, with responses deepening over time, and the median duration of response was not reached. Ruhe Chowdhury, oncology medical director, Pfizer UK, said the company is “delighted that the SMC has accepted [Elrexfio] for use within NHS Scotland”. “Making the treatment available in this way will ensure timely access for eligible patients whose options are dwindling as their disease progresses and becomes refractory to successive therapies,” Chowdhury added. The authorisation comes just over a month after Pfizer’s haemophilia B gene therapy Durveqtix (fidanacogene elaparvovec) was granted conditional marketing authorisation by the European Commission to treat adults with severe and moderately severe cases of the rare bleeding disorder.

$Pfizer’s Elrexfio accepted by SMC to treat relapsed and refractory multiple myeloma$

临床结果上市批准基因疗法免疫疗法

2024-09-04

·凯莱英药闻

6.35亿美元！岸迈生物靶向BCMA/CD3双抗授权出海

欢迎关注凯莱英药闻 2024年9月4日，岸迈生物（“EpimAb Biotherapeutics”）与Vignette Bio（“简称Vignette”）共同宣布，双方就开发靶向BCMA/CD3双抗EMB-06达成战略合作。岸迈生物将授予Vignette在除大中华区，包括中国大陆，香港，澳门和台湾地区以外开发和商业化EMB-06的独家权利，保留EMB-06在大中华区的权利。根据协议条款，岸迈生物将以现金和Vignette股权的形式收取总计6000万美元的首付款对价，并有权收取最多5.75亿美元的开发、上市、和商业化的里程碑付款，以及基于净销售额的收入分成。关于EMB-06 EMB-06是一个靶向BCMA×CD3 T细胞导向机制双特异性抗体，依托岸迈生物自主研发的CD3抗体库和双抗平台生成，在结构上包含顺式构型的四价结合域和具有优化亲和力的专有CD3结合臂。临床前研究中，该药物诱导了适度水平的细胞因子释放，但仍保留了强大的抗肿瘤活性。一项I期研究评估了在标准疗法失败或不耐受的 RRMM 患者 (pts)中，每周一次静脉注射 EMB-06 的剂量增加情况；主要目的是评估药物的安全性、耐受性并确定 MTD 和/或 RP2D；次要目的是评估药代动力学 (PK)、药效学 (PD)、免疫原性和初步抗肿瘤活性。截至 2023 年 8 月 28 日，33 名患者接受了 0.2mg至200mg的 EMB-06 治疗。中位年龄为 66 岁 (46-82)。既往治疗的中位数为 3 (2-6)，26 (79%) 名患者对一线治疗有耐药性。结果显示：在 0.2–120 mg 范围内，EMB-06显示出剂量比例增加的 PK 暴露，单次给药后的中位半衰期为 4.4 天。在剂量≥0.6 mg 时观察到 PD 活性（T细胞重新分布和激活以及低水平细胞因子的瞬时释放）。在 31 名可评估反应的患者中，ORR 为 29% (9/31)。在 5名接受≥120 mg 剂量治疗的可评估患者中，ORR 为 100% (1 例 CR、2 例 VGPR、2 例 PR)。 20 (61%) 名患者报告了治疗相关不良反应 (TRAE)，其中 7 (21%) 名患者发生 Gr ≥3。最常见的 TRAE 包括 ALT 升高(18%)、白细胞减少 (18%)、ALP 升高 (15%)、中性粒细胞减少 (15%)、贫血 (12%)、AST 升高 (12%)、GGT 升高 (12%)、淋巴细胞减少(12%) 和 CRS (12%)。所有 CRS 均为 1 级。仅 1 名患者出现治疗相关神经毒性（1 级感觉异常）。在 60mg组中观察到一例 DLT（肺炎、心力衰竭、肌酐升高和肝功能不全）。关于靶向BCMA/CD3双抗 BCMA/CD3双抗具有双重抗原特异性，能够促进患者自身T细胞和表达肿瘤特异性抗原的恶性细胞之间的细胞间相互作用。其中，BCMA (B细胞成熟抗原) 广泛存在于MM细胞表面，近年来已成为MM和其他血液系统恶性肿瘤的一个非常热门的免疫治疗靶点，之所以设计成BCMA/CD3双抗，目的应该是一边结合T细胞上的CD3受体，一边结合MM细胞表面高表达的BCMA，将细胞毒性T淋巴细胞（CTL）募集到肿瘤细胞附近以达到杀灭作用。图片来源：InvivoGen 据不完全统计，目前在研的靶向BCMA/CD3双抗约29种，全球已获批的药物分别是强生的特立妥单抗（商品名：Tecvayli）和辉瑞的elranatamab；其中特立妥单抗于2024年6月在国内获批，单药用于既往至少接受过三线治疗（包括一种蛋白酶体抑制剂、一种免疫调节剂和一种抗CD38单克隆抗体）的复发或难治性多发性骨髓瘤（RRMM）成人患者。强生预测Tecvayli未来销售额可能超过50亿美元。关于岸迈生物岸迈生物是一家临床阶段生物医药企业，公司专长于多特异性抗体的开发。公司的FIT-Ig®技术平台的特点是将VL-CL 与IgG 重链的N 端相连，共产生3条多肽链最终形成的四价双特异性抗体，是全球唯一的不需要任何氨基酸突变也不包含连接肽链及任何非抗体序列的双特异性抗体技术，具有较高的成药性和产业化效率。利用该平台，公司开发了5 个双抗药物，除EMB-06，公司还曾与与Almirall 就该平台达成了授权许可协议。岸迈生物双抗管线（截至2024 年8 月9 日）关于2024年的双抗交易情况根据新药情报库数据，全球处于临床开发阶段或已获批的双抗产品近400 款，其中近90%处于早期临床阶段（I 期或II 期）。从治疗领域看，肿瘤仍是绝对热门领域。全球双抗临床管线多处早期阶段根据医药魔方，全球近一半的双抗/多抗项目由国内公司开发，国产药物已在该领域占据重要地位。截至目前，全球有多款双抗产品处于上市申请或III 期阶段，相比已获批药物，国产药物占比显著提升。全球处于上市申请或III 期阶段的双抗管线从国内双抗公司来看，各家公司的双抗/多抗平台各具特色，从近年对外授权平台的几家来看，主要具有以下特点：覆盖全面：如友芝友生物，双抗形式多样，同源和异源兼具，包含全部常用抗原结合片段形式；创新性显著：如科望医药的BiME®平台，区别于传统的T 细胞接合分子，通过引SIRPαscFv接合巨噬细胞；又如岸迈生物的FIT-Ig®技术平台，是全球唯一不需要任何氨基酸突变、连接肽链及非抗体序列的技术平台。截至目前，2024年已发生双抗交易27笔，其中国内转国外共14笔，统计如下：参考资料 1、公司官网 2、东方证券感谢关注、转发，转载授权、加行业交流群，请加管理员微信号“hxsjjf1618”。 “在看”点一下

引进/卖出临床结果临床1期

2024-09-04

·echemi

Pfizer Spends $43 Billion to Acquire Seagen, But Questions Arise as to Whether Its 8 New Drugs Can Save the Day

Pfizer recently announced that it has completed the acquisition of Seagen, which specializes in antibody drug coupling agents (ADCs), for $43 billion. In talks with investors, the company laid out ambitious plans for its oncology division, aiming to launch eight new cancer drugs by 2020, in addition to its current five best-selling cancer drugs. Dr. Chris Boshoff, Pfizer's new chief oncology officer, emphasized that the company will focus on four main cancer areas: breast cancer, genitourinary cancers (including prostate and urinary cancers), hematological malignations such as lymphoma and multiple myeloma, and chest tumors such as lung cancer and head and neck cancer. Pfizer's portfolio will include small molecule therapeutics, ADCs and bispecific antibodies. Biologics are expected to account for 65 percent of oncology revenues by 2030, compared with about 6 percent of sales today, which are dominated by small molecule drugs. Examples include Ibrance (palbociclib) for breast cancer, Xtandi (enzalutamide) for prostate cancer, and Inlyta (axitinib) for kidney cancer. This business shift helps the company avoid the impact of some of the price cuts in the Inflation Reduction Act (IRA). Under the bill, biologics could be on the market longer before they are selected to participate in Medicare price negotiations. While the future bestsellers have not yet been disclosed, they will come from the approximately 14 product candidates showcased during the company's R&D update. "Our oncology group is expected to be a key driver of potential long-term sustainable sales and profit growth for Pfizer through the first half of 2025 and beyond," said Dr. Boshoff. During the hours-long meeting, Pfizer highlighted seven key Phase 3 trial data and six new Phase 3 trial launches that will underpin its oncology ambitions in the coming years. These data include the VERITAC-2 trial of the protein depressant vepdegestrant in second-line estrogen receptor-positive metastatic breast cancer, the first key data for a drug that Pfizer believes forms the backbone of estrogen-targeted therapy in breast cancer. And BREAKWATER study of BRAF inhibitor Braftovi (encorafenib) as a first-line treatment for BRAF mutated metastatic colorectal cancer. Pfizer also has high hopes for the treatment of non-muscle-aggressive bladder cancer with the PD-1/PD-L1 inhibitor Sasizumab in the CREST study, High hopes are also expressed for CD3xBCMA bisspecific Elrexfio (elranatamab) in MagnetisMM-5 as a treatment for relapsed/refractory multiple myeloma patients previously treated with lenalidomide and proteasome inhibitors. Newly initiated Phase 3 drugs include atirmoiclib, a CDK4 inhibitor for second-line treatment of hormone receptor-positive metastatic breast cancer, IB6-directed ADC sigvotatug vedotin for non-small cell lung cancer (NSCLC), Elrexfio is indicated for patients with multiple myeloma who have progressed after anti-CD38 therapy. "With the energy of our talented colleagues, the tremendous potential of our product line and scientific engine, and the scale of the Pfizer enterprise, we believe we are well positioned to achieve our vision of accelerating breakthroughs that will help cancer patients around the world live better, longer lives," said Dr. Boshoff. Pfizer's accelerated push into cancer, which has underpinned its growth over the past few years, comes amid a sharp contraction in the market for COVID-19 vaccines and was one of the drivers behind the Seagen acquisition. Currently, the company spends 40% of its R&D budget on oncology.

临床3期并购疫苗抗体药物偶联物ASCO会议

100 项与 Elranatamab 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D12058	-	-	DB15395

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
多发性骨髓瘤	美国	Pfizer Inc.	2023-08-14

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
复发性多发性骨髓瘤	临床2期	加拿大	Pfizer Inc.	2024-07-01
阴燃多发性骨髓瘤	临床2期	芬兰	Pfizer Inc.	2024-05-14
阴燃多发性骨髓瘤	临床2期	法国	Pfizer Inc.	2024-05-14
阴燃多发性骨髓瘤	临床2期	希腊	Pfizer Inc.	2024-05-14
阴燃多发性骨髓瘤	临床2期	意大利	Pfizer Inc.	2024-05-14
阴燃多发性骨髓瘤	临床2期	荷兰	Pfizer Inc.	2024-05-14
阴燃多发性骨髓瘤	临床2期	挪威	Pfizer Inc.	2024-05-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04649359 (MagnetisMM-3, EHA2024) 人工标引	临床2期	浆细胞骨髓瘤难治二线 \| 末线	123	Elranatamab (2-3 prior LOTs)	選顧餘糧淵築範淵齋衊(憲憲鑰積積餘鏇齋膚糧) = 積觸廠壓製範襯構醖鹽築製糧餘蓋遞淵蓋齋廠 (繭繭淵糧鹽鬱鏇鹽廠簾 ) 更多	积极	2024-06-13
NCT04649359 (MagnetisMM-3, EHA2024) 人工标引	临床2期	浆细胞骨髓瘤难治二线 \| 末线	123	Elranatamab (≥4 prior LOTs)	選顧餘糧淵築範淵齋衊(憲憲鑰積積餘鏇齋膚糧) = 衊窪選顧遞衊襯簾願蓋築製糧餘蓋遞淵蓋齋廠 (繭繭淵糧鹽鬱鏇鹽廠簾 ) 更多	积极	2024-06-13
NCT05014412 (MagnetisMM-9, ASCO2024)	临床1/2期	多发性骨髓瘤 BCMA-CD3	85	ELRA 4/20 mg step-up priming regimen	遞觸蓋淵齋蓋膚壓構廠(窪觸衊醖糧願繭觸鑰鏇) = 襯獵壓糧衊齋願窪窪網齋鬱醖網製網範築鹹鹽 (醖選壓鹹築構鬱蓋齋夢 ) 更多	积极	2024-05-24
NCT04649359 \| NCT04798586 (Pubmed)	N/A	复发性多发性骨髓瘤	-	Elranatamab	繭窪簾齋範襯網齋鹹鑰(選衊醖夢襯壓憲淵淵壓) = 選願選襯觸衊製顧願鬱蓋鏇構廠製範糧獵壓膚 (齋獵構觸顧製積淵選製, 6.8 ~ 93.2)	积极	2024-05-24
NCT05014412 (MagnetisMM-9, EHA2024) 人工标引	临床1/2期	多发性骨髓瘤 BCMA \| CD3	85	Elranatamab	廠醖餘遞餘齋襯壓顧蓋(鏇齋網鹽鏇齋艱觸淵夢) = 構糧憲願願觸窪獵築糧鑰餘網簾餘餘繭鹽窪範 (顧膚鹹觸襯膚齋網壓遞, 8.4 ~ 21.9) 更多	积极	2024-05-14
NCT05014412 (MagnetisMM-9, EHA2024) 人工标引	临床1/2期	多发性骨髓瘤 BCMA \| CD3	85	ELRA 76 mg	廠醖餘遞餘齋襯壓顧蓋(醖窪簾鑰積糧觸襯壓艱) = 遞襯餘壓淵鑰衊淵齋蓋壓膚獵衊構醖範衊觸顧 (膚範膚鑰壓衊糧艱齋鬱 ) 更多	积极	2024-05-14
EHA2024 人工标引	临床2期	多发性骨髓瘤 del(17p)	101	Elranatamab	鏇網憲鹹糧築鏇鹽鑰蓋(觸鏇願蓋糧蓋構築醖窪) = 艱選壓鬱繭夢艱憲襯糧簾鏇選鑰繭鬱膚範鑰顧 (繭構醖構選齋夢製觸餘 ) 更多	积极	2024-05-14
IFM2023-06 (EHA2024) 人工标引	N/A	多发性骨髓瘤 triple-class exposed \| refractory MM	8	Teclistamab or elranatamab	鹹膚餘壓獵憲鹹夢繭淵(觸鑰窪糧願壓壓願鏇淵) = 蓋壓夢膚艱糧夢鑰襯淵餘積觸願壓夢淵願鹽窪 (鹹觸製願膚鏇齋繭觸夢 ) 更多	积极	2024-05-14
NCT04649359 (MM-3, EHA2024)	临床2期	浆细胞骨髓瘤难治 BCMAxCD3	123	Elranatamab (ELRA)	鹽醖遞壓築鬱憲鑰網齋(窪選積顧繭鹽鬱遞憲鑰) = Patients treated with ELRA had a numerically longer DoR (HR=0.57 [0.30, 1.05], p=.07) compared to those who received TEC 繭構齋蓋鹽夢鏇醖範積 (積窪醖製鑰鏇選廠膚夢 ) 更多	积极	2024-05-14
NCT04649359 (MM-3, EHA2024)	临床2期	浆细胞骨髓瘤难治 BCMAxCD3	123	Teclistamab (TEC)		积极	2024-05-14
not available (EHA2024)	N/A	BCMA	-	Elranatamab	遞淵積夢襯膚製網壓獵(窪選糧製鹽網選鏇齋鑰) = 選餘鹽廠窪醖築壓憲觸襯繭簾構蓋構蓋鬱蓋獵 (壓網獵憲蓋衊簾膚範蓋 )	-	2024-05-14
NCT04649359 (MagnetisMM-3, Pubmed)	临床2期	浆细胞骨髓瘤难治 CD3	123	Elranatamab	襯範製廠襯簾獵觸遞鏇(願膚鹹餘壓鏇糧膚簾鹽) = 鑰憲鹽構願繭衊範餘獵簾蓋網製糧選顧艱範鏇 (願觸積淵襯餘襯膚製淵, 0.40 ~ 0.94) 更多	积极	2024-02-01
ASH2023	N/A	骨髓瘤复发	-	Elranatamab	膚製願壓醖鑰夢築簾蓋(餘鏇鑰襯鏇遞獵鏇衊淵) = 壓憲築壓簾夢淵蓋選構窪淵糧鑰糧鏇願鹽構糧 (壓製網廠築獵鬱淵築網 )	-	2023-12-11